TABLE 3.
Study sample characteristics of the antihypertensive pharmacotherapy adherence profile.
| Patient characteristic | Total n = 117* (%) | SMAQ classification | p | MGL classification | p | |||
|---|---|---|---|---|---|---|---|---|
| Adherent n (%) | Non-adherent n (%) | Adherent n (%) | Non-adherent n (%) | |||||
| Sex | Male | 32 (27.4) | 8 (25.0) | 24 (75.0) | 0.82 | 13 (40.6) | 19 (59.4) | 0.82 |
| Female | 85 (72.6) | 23 (27.1) | 62 (72.9) | 29 (34.1) | 56 (65.9) | |||
| Schooling | Illiterate | 14 (12.0) | 4 (28.6) | 10 (71.4) | 0.90 | 7 (50.0) | 7 (50.0) | 0.73 |
| Kindergarten | 4 (4.3) | 2 (50.0) | 2 (50.0) | 1 (25.0) | 3 (75.0) | |||
| Elementary school | 17 (14.5) | 4 (23.5) | 13 (76.5) | 4 (36.8) | 13 (63.2) | |||
| Middle school | 38 (32.5) | 10 (22.6) | 28 (77.4) | 14 (38.7) | 24 (61.3) | |||
| High school | 31 (26.5) | 7 (22.6) | 24 (77.4) | 12 (38.7) | 19 (61.3) | |||
| College | 13 (11.1) | 4 (30.8) | 9 (69.2) | 4 (30.8) | 9 (69.2) | |||
| Hypertension diagnosis time | 6–11 months | 3 (2.6) | 1 (33.3) | 2 (66.7) | 0.83 | 2 (66.7) | 1 (33.3) | 0.28 |
| 1–4 years | 32 (27.6) | 10 (31.3) | 22 (68.7) | 9 (28.1) | 23 (71.9) | |||
| 5–9 years | 20 (17.2) | 4 (20.0) | 16 (80.0) | 5 (25.0) | 15 (75.0) | |||
| More than 10 years | 61 (52.6) | 16 (26.2) | 45 (73.8) | 25 (41.0) | 36 (59.0) | |||
| Comorbidity | No | 38 (32.5) | 7 (18.4) | 31 (81.6) | 0.17 | 10 (26.3) | 28 (73.7) | 0.13 |
| Yes | 79 (67.5) | 24 (30.4) | 55 (69.6) | 32 (40.5) | 47 (59.5) | |||
Pearson’s chi-squared, significance level p < 0.05; * in the item “hypertension diagnosis time,” we considered a total of 116 respondents.